Delving into the Latest Updates on AoBio Co., Ltd. with Synapse

Overview

Tags

Neoplasms

Nervous System Diseases

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	4
Nervous System Diseases	1

Top 5 Drug Type	Count

Small molecule drug	4

Top 5 Target	Count

CNOT1(CCR4-NOT transcription complex subunit 1)	1
ARF1(ADP ribosylation factor 1)	1
GPCR(G-protein coupled receptor)	1

（1）剂量递增阶段（Ia）：主要目的：评估 AOB01-0036 胶囊单药在晚期实体瘤患者的安全性和耐受性，确定 AOB01-0036 胶囊的扩展期推荐剂量（RDE）和/或最大耐受剂量（MTD）（如有）。次要目的：评估 AOB01-0036 胶囊单药在晚期实体瘤患者中的药代动力学（PK）特征和药效动力学（PD）特征；初步评估 AOB01-0036 胶囊单药在晚期实体瘤患者中的抗肿瘤活性；评估AOB01-0036 胶囊在晚期实体瘤患者中的食物影响。（2）剂量扩展阶段（Ib）主要目的：评估 AOB01-0036 胶囊单药在晚期特定瘤种实体瘤患者中的有效性及为 II 期推荐剂量（RP2D）。次要目的：评估 AOB01-0036 胶囊单药在晚期特定瘤种实体瘤患者的安全性和耐受性；以其他疗效终点评估 AOB01-0036 胶囊单药在晚期特定瘤种实体瘤患者中的有效性；评估AOB01-0036 胶囊在晚期特定瘤种实体瘤患者中的 PK/PD 特征。

[Translation]

(1) Dose Escalation Phase (Ia): Primary Objective: To evaluate the safety and tolerability of AOB01-0036 capsules as monotherapy in patients with advanced solid tumors, and to determine the recommended dose (RDE) and/or maximum tolerated dose (MTD) (if any) for the extended phase of AOB01-0036 capsules. Secondary Objectives: To evaluate the pharmacokinetic (PK) and pharmacodynamic (PD) characteristics of AOB01-0036 capsules as monotherapy in patients with advanced solid tumors; to preliminarily assess the antitumor activity of AOB01-0036 capsules as monotherapy in patients with advanced solid tumors; and to evaluate the food effects of AOB01-0036 capsules in patients with advanced solid tumors. (2) Dose Expansion Phase (Ib): Primary Objective: To evaluate the efficacy of AOB01-0036 capsules as monotherapy in patients with advanced solid tumors of a specific type and to determine the recommended dose (RP2D) for Phase II. Secondary objectives: To evaluate the safety and tolerability of AOB01-0036 capsule monotherapy in patients with advanced-stage solid tumors of specific types; to evaluate the efficacy of AOB01-0036 capsule monotherapy in patients with advanced-stage solid tumors of specific types using other efficacy endpoints; and to evaluate the PK/PD characteristics of AOB01-0036 capsule in patients with advanced-stage solid tumors of specific types.

Start Date-

Sponsor / Collaborator

AoBio Co., Ltd.

100 Clinical Results associated with AoBio Co., Ltd.

Login to view more data

0 Patents (Medical) associated with AoBio Co., Ltd.

Login to view more data

100 Deals associated with AoBio Co., Ltd.

Login to view more data

100 Translational Medicine associated with AoBio Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 15 Nov 2026

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

3

1

Phase 1

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

AOB01-0036 ( ARF1 )	Advanced Malignant Solid Neoplasm More	Phase 1
AOB-04	Glioma More	Preclinical
AOB-03 ( GPCR )	Solid tumor More	Preclinical
AOB-02 ( CNOT1 )	Solid tumor More	Preclinical